Singapore, Dec. 9 -- Pillar Biosciences andAstraZeneca have announced an expansion of their existing laboratory access programme for NGS-based kitted liquid biopsy tumuor profiling to include China.

This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local availability of plasma-based tumour profiling at leading clinical laboratories in China, the partnership seeks to accelerate diagnostic turnaround times and improve access to precision oncology solutions.

As part of the initiative, AstraZeneca, Pillar Biosciences, and Shanghai Zhengu Biological Technology Co. will collaborate to support assay validationin local hospital laborator...